Skip to main content

Day: May 23, 2021

NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH

Written by Customer Service on . Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating 0.3 mg, 1 mg and 3 mg doses of aldafermin versus placebo in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis. Conference call and webcast details are as follows: Live Conference CallDomestic Callers: (844) 873-0551International Callers: (602) 563-8472Passcode: 9393531 Live and Archived Webcast                                   For the live or archived webcast, please visit the “Investors & Media” section of NGM’s website at https://ir.ngmbio.com/. The webcast will be archived for 30 days. Archived Conference...

Continue reading

Euro Manganese provides update on Chvaletice Manganese Project

Written by Customer Service on . Posted in Public Companies.

Permitting process, Demonstration Plant, feasibility study and commercial negotiations all remain on trackTarget development timelineTarget development timelineHighlights:The Project’s Final Environmental and Social Impact Assessment is on track for completion in the first quarter of 2022. Procurement of 97% of the Chvaletice Manganese Project’s Demonstration Plant equipment has been completed. Operation of the Demonstration Plant is scheduled to begin in the first quarter of 2022. Work on the Project’s definitive feasibility study is on track for completion in the first quarter of 2022. Euro Manganese continues its discussions with potential offtakers for the Chvaletice Manganese Project’s production of high purity manganese.VANCOUVER, British Columbia, May 23, 2021 (GLOBE NEWSWIRE) — Euro Manganese Inc....

Continue reading

Consolidated Unaudited Interim Report of AS PRFoods for the 3nd quarter and 9 months of 2020/2021 financial year

Written by Customer Service on . Posted in Public Companies.

MANAGEMENT COMMENTARY The most difficult year in PRFoods history is coming to close. Second wave of corona crisis lasted longer than predicted and in reality we have operated under restrictions the entire financial year ending in June. HoReCa has been closed, export logistics has been hindered and Norwegian salmon farmers dumped salmon at record low prices, that led to decrease of entire market. All this is reflected in our financial performance. Unfortunately we must admit that previous management made mistakes in investments and did not react to changed environment fast enough in Finland, thus amplifying the negatiive effect of corona. UK operations have been consistently profitable and from the beginning of calendar year we have resumed pre-coroan profitability and we see strong growth in sales and profitability for next financial...

Continue reading

Hexagon Composites ASA share buy-back program

Written by Customer Service on . Posted in Mergers And Acquisitions.

Reference is made to the stock exchange announcement of 21 May 2021 regarding the Company’s initiation of a share buy-back program. The program has been discontinued to ensure the Company operates within stipulated distribution limitations pertaining to certain financial arrangements. The discontinuation has resulted in no additional treasury shareholding as of end 21 May 2021. For more information: David Bandele, CFO, Hexagon Composites Telephone: +47 920 91 483 | david.bandele@hexagongroup.com About Hexagon Composites ASA Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation and conversion to clean energy in a wide range of mobility, industrial and consumer applications. Learn more at www.hexagongroup.com and follow @HexagonASA on Twitter and LinkedIn.This information...

Continue reading

InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19

Written by Customer Service on . Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) — InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society for Aerosols in Medicine (ISAM) Congress. Pharmacokinetic studies on inhalable liposomal GS-441524 (named ISPM21) and inhalable liposomal hydroxychloroquine (named ISPM19) showed significantly higher concentrations in the lungs than their conventional counterparts, giving ISPM21 and ISPM19 potential as prophylaxis and/or treatment for COVID-19. GS-441524 is main plasma metabolite of the antiviral prodrug remdesivir, which is approved in the US for the treatment...

Continue reading

PUBLICATION OF THE 2020 ANNUAL REPORT

Written by Customer Service on . Posted in Public Companies.

Solutions 30 today announced the release of its annual report for the year ended December 31, 2020. This report is available on the company’s website solutions30.com. This annual report includes:The consolidated financial statements at 12/31/2020 as approved by its supervisory board on 05/21/2021 and which remain unchanged. The report on corporate governance. The statutory auditor’s fees amounting to €2.4 million, representing an increase of more than 30% compared to 2019 (the year when IFRS were adopted).It also includes the report from statutory auditor EY, which indicates their “Disclaimer of opinion.” “We were engaged to audit the consolidated financial statements of Solution 30 SE (the “Group”), which comprise the consolidated statement of financial position as at 31 December 2020, and the consolidated statement of comprehensive...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.